Summit Therapeutics
Develops Akeso-origin ivonescimab through multinational late-stage oncology trials.
$13.71
After-hours close+0.00 (+0.03%)
At close$13.71(−4.33%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 17.16%Insiders —
Shares outstanding 797.75M · Float 110.35M · 13.8% free float
Insiders — filings are in another share unit.
The Form 4 positions here total more than the shares outstanding, so the filings and the share count are not on the same basis — usually an unlisted unit behind the listed one — and no insider percentage is shown.
Institutions13F, as of Jun 30, 2026
268 holders · 136.91M shares · 60 new positions · 159 increased · 57 reduced · 38 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Baker Bros. Advisors LP | 32.79M | 4.11% | −3.60M | Aug 14, 2026 |
| FMR LLC | 10.04M | 1.26% | −809.3K | Aug 13, 2026 |
| State Street Corp | 9.54M | 1.20% | +2.51M | Aug 7, 2026 |
| BlackRock, Inc. | 9.53M | 1.19% | −124.7K | Aug 7, 2026 |
| Vanguard Capital Management LLC | 5.73M | 0.72% | +22.7K | Aug 13, 2026 |
| UBS Group AG | 5.23M | 0.66% | +1.55M | Aug 13, 2026 |
| Vanguard Portfolio Management LLC | 5.04M | 0.63% | −191.1K | Aug 13, 2026 |
| Goldman Sachs Group Inc | 4.51M | 0.57% | +4.20M | Aug 14, 2026 |
Beneficial owners13D/G · 5% or more, as filed
No 13D/G filer at 5% or more on record.
InsidersForm 4
| Insider | Role | Shares | Filed |
|---|---|---|---|
| Robert W. Duggan | director, 10 percent owner, officer: Co-Chief Executive Officer | 599.71M | Jun 12, 2026 |
| Mahkam Zanganeh | director, 10 percent owner, officer: Co-Chief Executive Officer | 573.88M | Jun 12, 2026 |
| Yu Xia | director | 32.06M | Oct 23, 2025 |
| Manmeet Singh Soni | director, officer: COO and CFO | 3.10M | Jun 4, 2026 |
| Bhaskar Anand | officer: Chief Accounting Officer | 159.8K | Oct 23, 2025 |
4 people have not refiled in the last 18 months (429.4K shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Jun 12, 2026 | Robert W. Duggandirector, 10 percent owner, officer: Co-Chief Executive Officer | Purchase | 3,810,000 | $13.12 | 573,883,879 |
| Jun 12, 2026 | Mahkam Zanganehdirector, 10 percent owner, officer: Co-Chief Executive Officer | Purchase | 3,810,000 | $13.12 | 573,883,879 |
| Jun 4, 2026 | Manmeet Singh Sonidirector, officer: COO and CFO | Purchase · 2 lots | 50,000 | $14.45 | 3,123,603 |
| Jun 4, 2026 | Mahkam Zanganehdirector, 10 percent owner, officer: Co-Chief Executive Officer | Purchase | 100,000 | $14.60 | 25,824,474 |
| Jun 4, 2026 | Robert W. Duggandirector, 10 percent owner, officer: Co-Chief Executive Officer | Purchase | 100,000 | $14.60 | 25,824,474 |
| Oct 21, 2025 | Mahkam Zanganehdirector, 10 percent owner, officer: Co-Chief Executive Officer | Purchase | 26,680 | $18.74 | 76,680 |
| Oct 21, 2025 | Robert W. Duggandirector, 10 percent owner, officer: Co-Chief Executive Officer | Purchase | 26,680 | $18.74 | 76,680 |
| Oct 21, 2025 | Yu Xiadirector | Purchase | 533,617 | $18.74 | 32,057,147 |
| Sep 10, 2025 | Robert W. Duggandirector, 10 percent owner, officer: Co-Chief Executive Officer | Purchase | 333,394 | $17.68 | 556,088,090 |
| Sep 11, 2025 | Robert W. Duggandirector, 10 percent owner, officer: Co-Chief Executive Officer | Purchase | 5,000 | $18.07 | 556,093,090 |
CongressHouse and Senate disclosures
Not reported.